October 02, 2014 7:04 AM ET


Company Overview of Marinus Pharmaceuticals, Inc.

Company Overview

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.

142 Temple Street

Suite 205

New Haven, CT 06510

United States

Founded in 2003

4 Employees





Key Executives for Marinus Pharmaceuticals, Inc.

Executive Chairman
Age: 57
Total Annual Compensation: $370.9K
Chief Financial Officer
Age: 43
Total Annual Compensation: $30.0K
Chief Clinical Development & Regulatory Officer
Age: 50
Total Annual Compensation: $359.6K
Compensation as of Fiscal Year 2013.

Marinus Pharmaceuticals, Inc. Key Developments

Marinus Pharmaceuticals, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 03:00 PM

Marinus Pharmaceuticals, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 03:00 PM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, New York, New York, United States. Speakers: Edward F. Smith, Chief Financial Officer, Principal Financial & Accounting Officer, Vice President, Secretary and Treasurer.

Marinus Pharmaceuticals, Inc. Enters into Use Agreement with CyDex Pharmaceuticals, Inc. for Use of Captisol(R) for Ganaxolone IV

Marinus Pharmaceuticals, Inc. announced that it has entered into an agreement with CyDex Pharmaceuticals, Inc., a wholly owned subsidiary of Ligand Pharmaceutical Incorporated, for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous (IV) dose form of ganaxolone with Captisol.

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) added to NASDAQ Composite Index

Marinus Pharmaceuticals, Inc. will be added to the NASDAQ Composite Index.

Similar Private Companies By Industry

Company Name Region
Seroyal USA, Inc. United States
Elanco Animal Health, Inc. United States
HealthAsure, Inc. United States
Fitzgerald Industries International, Inc. United States
GeneraMedix, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Marinus Pharmaceuticals, Inc., please visit www.marinuspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.